Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Kura Oncology, Inc.NASDAQ: KURA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $355K rose 47.3% year over year, behind the +183.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 78.9% from the prior quarter.
Context
- Depreciation & amortization amounted to 11.0% of revenue in FY2025, up 9.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +47.3% toward the trailing-twelve-month pace of +183.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (7.46M) USD
- Year-over-year change
- -979.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.46M) | -979.2% |
| FY2024 | 2024-12-31 | 848K | -0.1% |
| FY2023 | 2023-12-31 | 849K | +11.9% |
| FY2022 | 2022-12-31 | 759K | +36.0% |
| FY2021 | 2021-12-31 | 558K | — |
Depreciation & Amortization vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 depreciation & amortization of $2.43M is the 3rd largest of the 11 companies compared; the peer median is $1.08M.
- Its year-over-year change of +183.7% is the 3rd highest of 11, against a peer median of +1.8%.
- Depreciation & amortization amounts to 3.4% of revenue for KURA, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2025 | $12.21M | +14.7% | +15.5% | 2.0% | |
| LTM Mar 2026 | $2.43M | +183.7% | — | 3.4% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.19M | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $1.17M | +120.2% | +56.5% | 222.3% | |
| LTM Mar 2026 | $997K | +3223.3% | — | 2.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $977K | +526.3% | — | — |
| LTM Mar 2026 | $541K | +0.2% | +22.6% | — | |
| LTM Sep 2026 | $152K | -97.9% | — | — | |
| LTM Mar 2026 | $102K | -2140.0% | -43.3% | 0.0% | |
| Peer median (excluding KURA) | $1.08M | +1.8% | +20.4% | 2.0% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | (7.46M) |
| Deferred Income Tax | 4.6M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.58M | 26.32M | 28.08M | 33.9M | 37.11M |
| Change in Working Capital | (3.22M) | (2.98M) | 7.82M | 286.17M | 184.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (6.74M) |
| Inventory | 0 | 0 | 0 | 0 | (413K) |
| Accounts Payables | (2.52M) | (802K) | 10.33M | 15.2M | 4.5M |
| Other Working Capital | (706K) | (2.18M) | (2.51M) | 270.97M | 187.1M |
| Other Non-Cash Items | 399K | 1.68M | (8.94M) | (12.62M) | 515K |
| Operating Cash Flow | (104.55M) | (110.06M) | (124.82M) | 134.32M | (64.06M) |
| Capital Expenditures | (1.15M) | (626K) | (168K) | (472K) | (6.64M) |
| Acquisitions (Net) | 125.69K | (33.25K) | 0 | 0 | 0 |
| Purchases of Investments | (445.66M) | (270.66M) | (409.82M) | (659.05M) | (761.59M) |
| Sales of Investments | 319.97M | 303.91M | 425.55M | 557.93M | 755.13M |
| Other Investing Activities | (125.69K) | 33.25K | 0 | 0 | 0 |
| Investing Cash Flow | (126.84M) | 32.63M | 15.56M | (101.59M) | (13.1M) |
| Debt Repayment | (7.25M) | 10M | 0 | 0 | 0 |
| Common Stock Issued | 4.43M | 24.72M | 93.58M | 145.81M | 1.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (611K) | 3.84M | 1.21M | 8.6M | 0 |
| Financing Cash Flow | (3.44M) | 38.57M | 94.78M | 154.42M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (234.82M) | (38.87M) | (14.48M) | 187.14M | (75.36M) |
| Free Cash Flow | (105.7M) | (110.69M) | (124.99M) | 133.85M | (70.7M) |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.